Hypoglycemia

May 06, 2025

FDA Approves Abeona’s ZEVASKYN as First Cell-Based Gene Therapy for RDEB The FDA approved Abeona Therapeutics’ ZEVASKYN (prademagene zamikeracel, or pz-cel), the first and only autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is d...

Sep 10, 2024

Biogen's Higher SPINRAZA Dose Shows Improved Efficacy in Phase II/III Trial A trial studying a higher dose of Biogen’s spinal muscular atrophy drug SPINRAZA (nusinersen) has met the primary endpoint in a cohort of infants with SMA. The Phase II/III DEVOTE study, which included 145 patients across various ages an...

Jul 25, 2019

FDA Approves Eli Lilly's Baqsimi, the first treatment for Severe Hypoglycemia The U.S. FDA gave its approval to Baqsimi nasal powder, for the treatment of Severe Hypoglycaemia in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the first non-injectable emergency t...

Jun 13, 2017

J&J's Invokana matches Jardiance's 14% reduction in major CV events There’s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits—and amputation risks—along with it. In a cardiovascular outcomes trial, Johnson & Johnson's Invokana matched up to Eli Lilly and Boehringer...